Observational studyDiabetes2018
Circulating Fetuin-A and Risk of Type 2 Diabetes: A Mendelian Randomization Analysis.
Open access · bronzeAbstract readComparative StudyMulticenter StudyObservational Study
In one paragraph
Observational study in Diabetes, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Role of the Genetic Variants of Fetuin-A and Adiponectin in Type 2 Diabetes Mellitus: A Narrative Review.Cureus · 2025Review
- Fetuin-A and Heme Oxygenase 1 as Potential New Markers in the Diagnosis of Diabetic Kidney Disease.International journal of molecular sciences · 2025Review
- CARDIAL-MS (CArdio-Renal-DIAbetes-Liver-Metabolic Syndrome): a new proposition for an integrated multisystem metabolic disease.Diabetology & metabolic syndrome · 2025Review
- Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment.Biomolecules · 2025Review
- Urinary Fetuin-A with Specific Post-Translational Modification in Type 1 Diabetes Patients with Normoalbuminuria and Preserved Kidney Function.Diagnostics (Basel, Switzerland) · 2025Article
- Inter-organ crosstalk during development and progression of type 2 diabetes mellitus.Nature reviews. Endocrinology · 2024Review
- Fetuin-A and its genetic association with cardiometabolic disease.Scientific reports · 2023Article
- Cardiac Hepatopathy: New Perspectives on Old Problems through a Prism of Endogenous Metabolic Regulations by Hepatokines.Antioxidants (Basel, Switzerland) · 2023Review
- The role of hepatokines in NAFLD.Cell metabolism · 2023Review
- Tissue chaperoning-the expanded functions of fetuin-A beyond inhibition of systemic calcification.Pflugers Archiv : European journal of physiology · 2022Review
- Fetuin-A and risk of diabetes-related vascular complications: a prospective study.Cardiovascular diabetology · 2022Observational
- The rapid endocytic uptake of fetuin-A by adherent tumor cells is mediated by Toll-like receptor 4 (TLR4).FEBS open bio · 2020Article
- No Independent Association of Circulating Fetuin-A with Insulin Sensitivity in Young Women.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2020Observational
- An atlas on risk factors for type 2 diabetes: a wide-angled Mendelian randomisation study.Diabetologia · 2020Article
- Fetuin-a expression profile in mouse and human adipose tissue.Lipids in health and disease · 2020Article
- Fetuin-A levels are increased in the adipose tissue of diabetic obese humans but not in circulation.Lipids in health and disease · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
43 authors at 20 institutions in 10 countries.
Janine KrögerDepartment of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.ORCID 0000-0002-7496-3665
Karina MeidtnerDepartment of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Norbert StefanGerman Center for Diabetes Research (DZD), München-Neuherberg, Germany.ORCID 0000-0002-2186-9595
Marcela GuevaraNavarre Public Health Institute, Pamplona, Spain.
Nicola D KerrisonMRC Epidemiology Unit, University of Cambridge, Cambridge, U.K.
Eva ArdanazNavarre Public Health Institute, Pamplona, Spain.
Dagfinn AuneDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, U.K.
Heiner BoeingGerman Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Miren DorronsoroCIBER de Epidemiología y Salud Pública, Madrid, Spain.
Courtney DowCenter for Research in Epidemiology and Population Health, INSERM U1018, Villejuif, France.
Guy FagherazziCenter for Research in Epidemiology and Population Health, INSERM U1018, Villejuif, France.ORCID 0000-0001-5033-5966
Paul W FranksLund University, Malmö, Sweden.ORCID 0000-0002-0520-7604
Heinz FreislingSection of Nutrition and Metabolism, International Agency for Research on Cancer, World Health Organization, Lyon, France.
Marc J GunterSection of Nutrition and Metabolism, International Agency for Research on Cancer, World Health Organization, Lyon, France.
José María HuertaCIBER de Epidemiología y Salud Pública, Madrid, Spain.
Rudolf KaaksDivision of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
Timothy J KeyUniversity of Oxford, Oxford, U.K.
Kay Tee KhawUniversity of Cambridge, Cambridge, U.K.
Vittorio KroghIstituto Nazionale dei Tumori, Fondazione IRCCS, Milan, Italy.
Tilman KühnGerman Cancer Research Center, Heidelberg, Germany.
Francesca Romana ManciniCenter for Research in Epidemiology and Population Health, INSERM U1018, Villejuif, France.
Amalia MattielloDipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy.
Peter M NilssonLund University, Malmö, Sweden.
Anja OlsenDanish Cancer Society Research Center, Copenhagen, Denmark.
Kim OvervadSection for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark.
Domenico PalliCancer Research and Prevention Institute, Florence, Italy.
J Ramón QuirósPublic Health Directorate, Asturias, Spain.
Olov RolandssonUmeå University, Umeå, Sweden.
Carlotta SacerdoteUnit of Cancer Epidemiology, Città della Salute e della Scienza Hospital-University of Torino, Center for Cancer Prevention, Torino, Italy.
Núria SalaUnit of Nutrition and Cancer, Cancer Epidemiology Research Programme, and Translational Research Laboratory, Catalan Institute of Oncology, Barcelona, Spain.
Elena Salamanca-FernándezCIBER de Epidemiología y Salud Pública, Madrid, Spain.
Ivonne SluijsJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Annemieke M W SpijkermanNational Institute for Public Health and the Environment, Bilthoven, the Netherlands.
Anne TjonnelandDanish Cancer Society Research Center, Copenhagen, Denmark.
Konstantinos K TsilidisDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, U.K.
Rosario TuminoAzienda Sanitaria Provinciale di Ragusa, Ragusa, Italy.
Yvonne T van der SchouwJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Nita G ForouhiMRC Epidemiology Unit, University of Cambridge, Cambridge, U.K.ORCID 0000-0002-5041-248X
Stephen J SharpMRC Epidemiology Unit, University of Cambridge, Cambridge, U.K.
Claudia LangenbergMRC Epidemiology Unit, University of Cambridge, Cambridge, U.K.
Elio RiboliSchool of Public Health, Imperial College London, London, U.K.
Matthias B SchulzeDepartment of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany mschulze@dife.de.ORCID 0000-0002-0830-5277
Nicholas J WarehamMRC Epidemiology Unit, University of Cambridge, Cambridge, U.K.
MRC Epidemiology Unit · GBInserm · FRCentre international de recherche sur le cancer · FRDanish Cancer Society · DKDeutsches Diabetes-Zentrum e.V. · DEGerman Cancer Research Center · DELund University · SENavarre Institute of Health Research · ESUtrecht University · NLAarhus University · DKAgenzia Regionale Sanitaria della Puglia · ITBasque Government · ESFederico II University Hospital · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITGerman Institute of Human Nutrition · DEGobierno del Principado de Asturias · ESImperial College London · GBInstitut Català d'Oncologia · ESInstituto de Investigación Biosanitaria de Granada · ESInstituto Murciano de Investigación Biosanitaria · ES
Funding
Cancer Research UK 14136Cancer Research UK 16491Cancer Research UK C8221/A19170Medical Research Council G0401527Medical Research Council G1000143Medical Research Council MC_UU_12015/1Medical Research Council MC_UU_12015/5Medical Research Council MR/M012190/1Medical Research Council MR/N003284/1World Health Organization 001
Abstract
Fetuin-A, a hepatic-origin protein, is strongly positively associated with risk of type 2 diabetes in human observational studies, but it is unknown whether this association is causal. We aimed to study the potential causal relation of circulating fetuin-A to risk of type 2 diabetes in a Mendelian randomization study with single nucleotide polymorphisms located in the fetuin-A-encoding
Indexed as
alpha-2-HS-GlycoproteinDiabetes Mellitus, Type 2AdultAgedBiomarkersCase-Control StudiesCohort StudiesEnzyme-Linked Immunosorbent AssayEuropeFemaleGenetic Association StudiesGermanyHumansImmunoturbidimetryIncidenceMaleAHSG protein, humanalpha-2-HS-GlycoproteinBiomarkers
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.